Bibliography
- OWENS D: Alternative routes of insulin delivery. Diabet. Med. (In Press).
- ••The best review on the subject.
- VON HEUBNER W, DE JONGH SE, LAQUER E: Uber inhalation von insulin. Kiln Wochenschrifr (1924) 51:2342–2343.
- LAUBE L, BENEDICT WG, DOBS AS: The lungs as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes. Chest (1998) 114:1734–1739.
- LAUBE L, GEORGOPOULOS GK: Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA (1993) 269:2106–2109.
- JENDLE H, KARLBERF E: Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scand. Clin. Lab. Investig. (1996) 56:555–561.
- HEINEMANN L, TRAUT T, HEISE T: Time-action profile of inhaled insulin. Diabet. Med. (1997) 14:63–72.
- GALE E: Two cheers for inhaled insulin. Lancet (2001) 357:324–325.
- ••Independent considerations on pros andcons of inhaled insulin.
- SELAM J-L: Insulin therapy in developedcountries. Int. Blab. Monitor. (2000) 12:1–3.
- WALL DA: Pulmonary absorption of peptides and proteins. Drug Delivery(1995) 2:1–20.
- HOMPESCH M, KAPITZA C, SCHARLING B, THOMSEN LK, HEISE T: Intra-subject variability of pulmonary insulin via the AERxR insulin diabetes management system versus subcutaneous insulin. Diabetologia (2001) 44\(Suppl. 1):813.
- GELFAND RA, SCHWARTZ SL, HORTON M, LAW CG, PUN EF: Pharmacological reproducibility of inhaled human insulin in patients with Type 2 diabetes mellitus. Diabetologia (2000) 43:773.
- HIMMELMANN A, JENDLE J, MELLEN A, PETERSEN AH, DAHL UL, WOLLMER P: The impact of smoking on inhaled insulin. Diabetes Care (2003) 3:677–682.
- SKYLERJS, CEFALU WT, KOURIDES IA et al.: Efficacy of inhaled human insulin in Type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet (2001) 357:331–335.
- ••The most irnpotant Type 1 diabetesmellitus report.
- CEFALU WT, SKYLERJS, KOURIDES IA et al.: Inhaled human insulin treatment in patients with Type 2 diabetes mellitus. Ann. Intern. Med. (2001) 134:203–207.
- ••The most important Type 2 diabetesmellitus report.
- LANDSCHULZ W: Exubera project: clinical update on inhaled insulin. 22'd AIDPIT meeting, Igls, Austria 26–28 January, 2003.
- FARR SJ WARREN SJ LLOYD P et al: Comparison of in vitro and in vivo efficiencies of a novel unit-dose aerosol generator and a pressurised metered dose inhaler. hat. Pharma. (2000) 198:63–70.
- MCELDUFF A, FARR S, WARD E et al:Comparison of the pharmacokinetics and pharmacodynamics of subcutaneous and inhaled insulin lispro in healthy fasted volunteers. Diabetes (1998) 47:413.
- BRUNNER GA, BALENT B, ELLMERER M et al.: Dose-response relation of liquid aerosol inhaled insulin in Type 1 diabetic patents. Diabetologia (2001) 44:305–308.
- EDWARDS DA, HANES J, CAPONETTI G et al.: Large porous particles for pulmonary drug delivery. Science (1997) 276:1868–1871.
- HEISE T: Alkermes Lilly project: time-action profile of new rapid acting inhaled insulin. 22'd AIDPIT meeting, Igls, Austria 26–28 January 2003.
- FISHMAN RS, GUINTA D, CHAMBERS F, QUINTANA R, SHAPIRO DA: Insulin administration via the Aerodose'" inhaler: Comparison to subcutaneously injected insulin. Diabetes (2000) 49\(Suppl. 1):38.
- MODI P: Oralin project: evolving role of Oralin in treatment of diabetes. 22'd AIDPIT meeting, Igls, Austria 26–28 January 2003.